CR11443A - Productos quimioterapeuticos cristalinos - Google Patents

Productos quimioterapeuticos cristalinos

Info

Publication number
CR11443A
CR11443A CR11443A CR11443A CR11443A CR 11443 A CR11443 A CR 11443A CR 11443 A CR11443 A CR 11443A CR 11443 A CR11443 A CR 11443A CR 11443 A CR11443 A CR 11443A
Authority
CR
Costa Rica
Prior art keywords
crystal
chemotherapeutic products
chemotherapeutic
products
indazol
Prior art date
Application number
CR11443A
Other languages
English (en)
Inventor
Michael J Rozema
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of CR11443A publication Critical patent/CR11443A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Forma cristalina 1 de N-[4-(3-amino-1H-indazol-4-il)fenil]-N'-(2-fluoro-5-metilfenil)urea, maneras para elaborarla, formulaciones que comprenden a la misma y elaboradas con la misma y metodos de tratamiento de pacientes que padecen una enfermedad para usarla.
CR11443A 2007-10-19 2010-05-19 Productos quimioterapeuticos cristalinos CR11443A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98125307P 2007-10-19 2007-10-19

Publications (1)

Publication Number Publication Date
CR11443A true CR11443A (es) 2010-09-27

Family

ID=40174807

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11443A CR11443A (es) 2007-10-19 2010-05-19 Productos quimioterapeuticos cristalinos

Country Status (18)

Country Link
US (1) US7960564B2 (es)
EP (1) EP2195301A1 (es)
JP (1) JP2011500707A (es)
KR (1) KR20100085987A (es)
CN (1) CN101827824B (es)
AU (1) AU2008312533A1 (es)
BR (1) BRPI0818334A2 (es)
CA (1) CA2699354A1 (es)
CO (1) CO6280484A2 (es)
CR (1) CR11443A (es)
DO (1) DOP2010000112A (es)
EC (1) ECSP10010176A (es)
GT (1) GT201000100A (es)
MX (1) MX2010004290A (es)
PA (1) PA8800601A1 (es)
RU (1) RU2010119919A (es)
UA (1) UA99489C2 (es)
WO (1) WO2009052230A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013022801A1 (en) 2011-08-05 2013-02-14 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
WO2012068549A2 (en) 2010-11-19 2012-05-24 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
WO2014152959A1 (en) 2013-03-14 2014-09-25 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
RU2017105844A (ru) 2014-08-08 2018-09-11 Форсайт Вижн4, Инк. Стабильные и растворимые составы ингибиторов рецепторных тирозинкиназ и способы их получения

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7297709B2 (en) * 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
DK1638941T3 (da) * 2003-05-22 2010-10-11 Abbott Lab Indazol-, benzisoxazol- og benzisothiazolkinaseinhibitorer
DE102005033100B3 (de) * 2005-07-15 2007-01-25 Sanofi-Aventis Deutschland Gmbh Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, diese Verbindung enthaltene Arzneimittel und Verfahren zu deren Herstellung
WO2007015569A1 (ja) * 2005-08-01 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を予測する方法
JP4989476B2 (ja) * 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
EP1959926A1 (en) 2005-10-25 2008-08-27 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
EP1962803A1 (en) * 2005-12-23 2008-09-03 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US20070173538A1 (en) * 2005-12-23 2007-07-26 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
EP2089003A1 (en) * 2006-11-09 2009-08-19 Abbott GmbH & Co. KG Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor

Also Published As

Publication number Publication date
RU2010119919A (ru) 2011-11-27
MX2010004290A (es) 2010-04-30
UA99489C2 (en) 2012-08-27
DOP2010000112A (es) 2010-07-15
US7960564B2 (en) 2011-06-14
EP2195301A1 (en) 2010-06-16
US20090124815A1 (en) 2009-05-14
CN101827824A (zh) 2010-09-08
AU2008312533A1 (en) 2009-04-23
JP2011500707A (ja) 2011-01-06
PA8800601A1 (es) 2009-05-15
ECSP10010176A (es) 2010-06-29
GT201000100A (es) 2012-04-12
WO2009052230A1 (en) 2009-04-23
BRPI0818334A2 (pt) 2017-05-16
CN101827824B (zh) 2012-10-03
CO6280484A2 (es) 2011-05-20
KR20100085987A (ko) 2010-07-29
CA2699354A1 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
CY1121017T1 (el) Κρυσταλλικες μορφες 5-χλωρο-ν2-(2-ισοπροποξυ-5-μεθυλ-4-πιπεριδιν-4-υλ-φαινυλ)-ν4-[2-(προπανο-2-σουλφονυλ)-φαινυλ]-πυριμιδιν-2,4-διαμινης
CY1112320T1 (el) Τιτλοδοτηση της ταπενταδολης
CY1112067T1 (el) Χρηση φλιμπανσερινης για την θεραπεια διαταραχων προ-εμμηνοπαυσιακης σεξουαλικης επιθυμιας
CO6341486A2 (es) Tratamiento y profilaxis de amiloidosis
CR11443A (es) Productos quimioterapeuticos cristalinos
CO6321285A2 (es) Uso de 3,11b-cis- dihidrotetrabenazina en el tratamiento de la esclerosis multiple y la mielitis autoinmunitaria
DOP2010000111A (es) Productos quimioterapeuticos cristalinos
MA32717B1 (fr) Sels de n-[6-cis- (2.6-dimethylmorpholin-4-yl)pyridin-3-yl)-2-methyl-4'- (trifluoromethoxy)- [1.1'-biphenyl]-3-carboxamide
AR062784A1 (es) Tratmiento de los vertigos con acetil -l- leucina
MX2010005465A (es) Tratamiento de disfagia faringea.
UY29777A1 (es) Utilización de agomelatina para la obtención de medicamentos destinados al tratamiento de trastornos del sueno en pacientes con depresión.
DOP2010000113A (es) Productos quimioterapeuticos cristalinos
ECSP077843A (es) Tratamiento o prevención del prurito
UY31407A1 (es) "productos quimioterapéuticos cristalinos"
EA200970816A1 (ru) Новая лекарственная форма
CR11386A (es) Productos quimioterapeuticos cristalinos
NO20071889L (no) Middel for profylakse eller behandling av stoffskiftesyndrom.
AR063895A1 (es) Utilizacion de la agomelatina para la obtencion de medicamentos destinados al tratamiento de la leucomalacia periventricular
CU20070232A7 (es) Utilización de la agomelatina para la obtención de medicamentos destinados al tratamiento de los trastornos bipolares
UY28498A1 (es) Modificación de cristal de un derivado de n-fenil-2-pirimidinamina, procesos para su fabricación y su uso.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)